Education
About Us
Working with TipRanks
Follow Us
Serina Therapeutics, Inc. (SER)
:SER
SER Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.81 - $10.28
Previous CloseN/A
Volume4.86K
Average Volume (3M)231.36K
Market Cap
$51.56M
Enterprise Value$60.73M
Total Cash (Recent Filing)$6.04M
Total Debt (Recent Filing)$185.00K
Price to Earnings (P/E)―
Beta-0.67
Next Earnings
Nov 18, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding10,250,588
10 Day Avg. Volume40,805
30 Day Avg. Volume231,359
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue467.15
Enterprise Value/Gross Profit30.36K
Enterprise Value/Ebitda-4.87
Forecast
1Y Price Target
$13.00Price Target Upside158.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Market PotentialMarket metrics appear extremely attractive with existing apomorphine drug/device combination products priced high, providing benchmarks for SER-252 pricing if approved.
Product DevelopmentSerina has announced a new once-weekly injectable asset in development for tardive dyskinesia, highlighting its POZ platform potential.
Regulatory ApprovalThe FDA's feedback supports the design of the trial under the 505(b)(2) NDA pathway, which could fast-track SER-252's regulatory path by allowing the company to use existing knowledge of apomorphine.
Bears Say
Bioavailability ChallengesSER-252 addresses issues of apomorphine administration comprehensively, particularly its poor bioavailability and injection site reactions.
Safety ConcernsThe company's global registrational program includes dose escalation overseen by a Safety Review Committee, which adds a layer of safety and credibility to their clinical trials.
Serina Therapeutics News
SER FAQ
What was Serina Therapeutics, Inc.’s price range in the past 12 months?
Serina Therapeutics, Inc. lowest stock price was $3.81 and its highest was $10.28 in the past 12 months.
What is Serina Therapeutics, Inc.’s market cap?
Serina Therapeutics, Inc.’s market cap is $51.56M.
When is Serina Therapeutics, Inc.’s upcoming earnings report date?
Serina Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 56 days.
How were Serina Therapeutics, Inc.’s earnings last quarter?
Serina Therapeutics, Inc. released its earnings results on Aug 11, 2025. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.425 by -$0.235.
Is Serina Therapeutics, Inc. overvalued?
According to Wall Street analysts Serina Therapeutics, Inc.’s price is currently Undervalued.
Does Serina Therapeutics, Inc. pay dividends?
Serina Therapeutics, Inc. does not currently pay dividends.
What is Serina Therapeutics, Inc.’s EPS estimate?
Serina Therapeutics, Inc.’s EPS estimate is -0.53.
How many shares outstanding does Serina Therapeutics, Inc. have?
Serina Therapeutics, Inc. has 10,250,588 shares outstanding.
What happened to Serina Therapeutics, Inc.’s price movement after its last earnings report?
Serina Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.425. Following the earnings report the stock price went up 7.059%.
Which hedge fund is a major shareholder of Serina Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SER
Serina Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (158.45% Upside)
$13.00 (158.45% Upside)
Insider Transactions
Sold Shares
Worth $618.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.60%
12-Months-Change
Fundamentals
Return on Equity
45.59%
Trailing 12-Months
Asset Growth
-16.50%
Trailing 12-Months
Company Description
Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
SER Stock 12 Month Forecast
Average Price Target
$13.00
▲(158.45% Upside)
Technical Analysis
PDS Biotechnology
―
Verrica Pharmaceuticals
―
Sutro Biopharma
―
Kronos Bio
―
Gain Therapeutics
―
Ownership Overview
62.56% Insiders
1.72% Mutual Funds
1.66% Other Institutional Investors
32.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---